Drug-induced aHUS is rare; however, early diagnosis is vital to reduce morbidity and mortality. With confirmation of the diagnosis, eculizumab appears to be a viable treatment option to suppress the pro-inflammatory surge. Furthermore, adverse side effects of medications such as carfilzomib and gemcitabine should be considered in the appropriate settings.
Keywords: Carfilzomib; eculizumab; gemcitabine; hemolytic–uremic syndrome; thrombotic microangiopathy; thrombotic thrombocytopenia purpura.